MX2020008446A - Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. - Google Patents
Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.Info
- Publication number
- MX2020008446A MX2020008446A MX2020008446A MX2020008446A MX2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A MX 2020008446 A MX2020008446 A MX 2020008446A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- treating cancer
- methods
- binding fragment
- ctla4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a métodos para el tratamiento contra el cáncer en un paciente, que comprenden administrar al paciente un anticuerpo anti-PD-1 o fragmento de unión a antígeno del mismo en cantidades específicas aproximadamente cada seis semanas, combinado administrar un anticuerpo anti-CTLA4 al paciente aproximadamente cada seis semanas. En determinadas modalidades, el antagonista de PD-1 es pembrolizumab o un fragmento de unión a antígeno del mismo. También se proporcionan composiciones que comprenden una dosificación de un anticuerpo anti-PD-1, o fragmento de unión a antígeno del mismo, y una dosificación de un anticuerpo anti-CTLA4 o fragmento de unión a antígeno del mismo, y usos del mismo para el tratamiento contra el cáncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862630038P | 2018-02-13 | 2018-02-13 | |
US201862732828P | 2018-09-18 | 2018-09-18 | |
US201862740741P | 2018-10-03 | 2018-10-03 | |
PCT/US2019/017188 WO2019160755A1 (en) | 2018-02-13 | 2019-02-08 | Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020008446A true MX2020008446A (es) | 2020-09-28 |
Family
ID=67620098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020008446A MX2020008446A (es) | 2018-02-13 | 2019-02-08 | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210047409A1 (es) |
EP (1) | EP3752193A4 (es) |
JP (2) | JP2021513540A (es) |
KR (1) | KR20200119845A (es) |
CN (1) | CN111727056A (es) |
AU (2) | AU2019222517A1 (es) |
BR (1) | BR112020015915A8 (es) |
CA (1) | CA3090996A1 (es) |
MA (1) | MA51844A (es) |
MX (1) | MX2020008446A (es) |
WO (1) | WO2019160755A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100054780A (ko) | 2007-06-18 | 2010-05-25 | 엔.브이.오가논 | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
WO2021178611A1 (en) * | 2020-03-05 | 2021-09-10 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody |
WO2021178657A1 (en) * | 2020-03-05 | 2021-09-10 | Merck Sharp & Dohme Corp. | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof |
WO2021213523A1 (zh) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 |
TW202305009A (zh) * | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
KR20240099187A (ko) * | 2021-10-29 | 2024-06-28 | 온코씨4, 아이앤씨. | 항-ctla-4 항체 투여 요법 |
CN113933520B (zh) * | 2021-11-15 | 2023-06-20 | 邹灵龙 | 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒 |
WO2024002074A1 (zh) * | 2022-06-28 | 2024-01-04 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
WO2024055005A2 (en) * | 2022-09-09 | 2024-03-14 | Adagene Pte. Ltd. | Activatable anti-ctla4 antibodies for treating cancer |
CN118767127A (zh) * | 2023-04-10 | 2024-10-15 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体的医药用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1212422T3 (da) * | 1999-08-24 | 2007-07-02 | Medarex Inc | Humane CTLA-4-antistoffer og anvendelserne deraf |
WO2006121168A1 (en) * | 2005-05-09 | 2006-11-16 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
KR20100054780A (ko) * | 2007-06-18 | 2010-05-25 | 엔.브이.오가논 | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
CA2955676A1 (en) * | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
WO2016176504A1 (en) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
DK3322731T3 (da) * | 2015-07-14 | 2021-03-08 | Bristol Myers Squibb Co | Fremgangsmåde til behandling af cancer ved hjælp af immun checkpoint-hæmmer; antistof der binder til programmed death-1-receptor (pd-1) eller programmed death ligand-1 (pd-l1) |
WO2017021911A1 (en) * | 2015-08-04 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
EP3331919A1 (en) * | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
KR20180088907A (ko) * | 2015-12-17 | 2018-08-07 | 노파르티스 아게 | Pd-1에 대한 항체 분자 및 그의 용도 |
US10358496B2 (en) * | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
EP4248990A3 (en) * | 2016-06-02 | 2024-01-03 | Bristol-Myers Squibb Company | Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma |
JP2019517512A (ja) * | 2016-06-03 | 2019-06-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 結腸直腸癌を有する患者の処置における抗pd−1抗体の使用 |
EP3464369A1 (en) * | 2016-06-03 | 2019-04-10 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treating a tumor |
CN110678199A (zh) * | 2017-05-02 | 2020-01-10 | 默沙东公司 | 单独的和与程序性死亡受体1(pd-1)抗体组合的抗ctla4抗体的稳定制剂及其使用方法 |
-
2019
- 2019-02-08 US US16/966,988 patent/US20210047409A1/en active Pending
- 2019-02-08 JP JP2020542952A patent/JP2021513540A/ja active Pending
- 2019-02-08 CN CN201980013384.1A patent/CN111727056A/zh active Pending
- 2019-02-08 AU AU2019222517A patent/AU2019222517A1/en not_active Abandoned
- 2019-02-08 MX MX2020008446A patent/MX2020008446A/es unknown
- 2019-02-08 EP EP19754385.3A patent/EP3752193A4/en active Pending
- 2019-02-08 MA MA051844A patent/MA51844A/fr unknown
- 2019-02-08 WO PCT/US2019/017188 patent/WO2019160755A1/en unknown
- 2019-02-08 CA CA3090996A patent/CA3090996A1/en active Pending
- 2019-02-08 KR KR1020207026005A patent/KR20200119845A/ko unknown
- 2019-02-08 BR BR112020015915A patent/BR112020015915A8/pt unknown
-
2023
- 2023-07-26 AU AU2023208115A patent/AU2023208115A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000161A patent/JP2024038250A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210047409A1 (en) | 2021-02-18 |
RU2020129075A (ru) | 2022-03-14 |
CA3090996A1 (en) | 2019-08-22 |
WO2019160755A1 (en) | 2019-08-22 |
AU2023208115A1 (en) | 2024-01-18 |
MA51844A (fr) | 2021-05-19 |
JP2024038250A (ja) | 2024-03-19 |
KR20200119845A (ko) | 2020-10-20 |
JP2021513540A (ja) | 2021-05-27 |
CN111727056A (zh) | 2020-09-29 |
BR112020015915A8 (pt) | 2023-01-31 |
EP3752193A4 (en) | 2022-02-23 |
EP3752193A1 (en) | 2020-12-23 |
AU2019222517A1 (en) | 2020-08-13 |
BR112020015915A2 (pt) | 2020-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
NZ769968A (en) | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy | |
BR112018012801A2 (pt) | combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 para tratar o câncer | |
CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
PH12020552115A1 (en) | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies | |
GEP20207166B (en) | Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use | |
MX2017005976A (es) | Moleculas de union especificas para grupo de diferenciacion 73 (cd73) y usos de las mismas. | |
MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
RU2014147867A (ru) | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов | |
AU2018290532A1 (en) | Immunotherapy for hepatocellular carcinoma | |
EA201990374A1 (ru) | Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков | |
MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
MX2021004226A (es) | Terapia combinada contra el cáncer. | |
MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. | |
MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
MX2021008760A (es) | Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
MX2022008421A (es) | Anticuerpo anti-galectina-9 y usos del mismo. | |
PH12020551451A1 (en) | Anti-cd25 for tumour specific cell depletion |